Back to top

Image: Bigstock

Foamix Pharmaceuticals (FOMX) Jumps: Stock Rises 15.7%

Read MoreHide Full Article

Foamix Pharmaceuticals Ltd. was a big mover last session, as its shares rose almost 16% on the day. The move came after the company said that a drug designed to treat papulopustular rosacea had shown strong results in a Phase 2 clinical trial. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $8.30 to $8.80 in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Foamix Pharmaceuticals currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is negative.

A better-ranked stock in the med-drugs space is BioSpecifics Technologies Corp. , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FOMX going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Published in